Alnylam Pharmaceuticals ((ALNY)), Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Alnylam Pharmaceuticals, in collaboration with Regeneron Pharmaceuticals, is conducting a Phase 1 study titled A Phase 1, Randomized, Placebo-controlled Study With a Double Blind Period With Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients With Alzheimer’s Disease. The study aims to assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of ALN-5288 in patients with Alzheimer’s Disease, marking a significant step in addressing this challenging condition.
Intervention/Treatment: The study tests ALN-5288, an experimental drug administered intrathecally, designed to evaluate its safety and effects in treating Alzheimer’s Disease. Participants will receive either ALN-5288 or a placebo during the double-blind period, followed by ALN-5288 in the open-label extension period.
Study Design: This interventional study employs a randomized, parallel assignment model with triple masking involving participants, care providers, and investigators. The primary purpose is treatment, focusing on evaluating the drug’s impact on Alzheimer’s Disease.
Study Timeline: The study is not yet recruiting, with the initial submission date on October 6, 2025. This marks the beginning of the study’s timeline, with primary and estimated completion dates yet to be announced, indicating the study’s early planning stages.
Market Implications: The initiation of this study could positively influence Alnylam and Regeneron’s stock performance as it represents a potential breakthrough in Alzheimer’s treatment. Investors may view this collaboration as a strategic move to capture a share of the lucrative Alzheimer’s market, enhancing both companies’ competitive positioning.
The study is ongoing, with further details available on the ClinicalTrials portal.